SIOX insider filings
Sio Gene Therapies Inc. — 17 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-02-10. Screen SIOX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for SIOX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Sio Gene Therapies Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-02-10 | 4 | Meswani Parag V — Chief Commercial Officer | Grant/award (A): 153,700 (derivative) @ $0 | EDGAR |
| 2022-02-10 | 4 | Nassif David W. — Interim CEO, CFO, Director | Grant/award (A): 546,500 (derivative) @ $0 | EDGAR |
| 2021-12-09 | 4 | Nassif David W. — Chief Financial Officer | Grant/award (A): 17,534 @ $0 · Tax withholding (F): 6,294 @ $1.42 · Disposition to issuer (D): 17,534 (derivative) @ $0 | EDGAR |
| 2021-12-09 | 4 | Cheruvu Pavan — Chief Executive Officer, Director | Grant/award (A): 37,567 @ $0 · Tax withholding (F): 14,884 @ $1.42 · Disposition to issuer (D): 37,567 (derivative) @ $0 | EDGAR |
| 2021-04-19 | 4 | Torti Frank — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2021-04-19 | 4 | Sundaram Senthil Vel — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2021-04-19 | 4 | Pande Atul — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2021-04-19 | 4 | Modig Berndt — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2021-04-19 | 4 | Nassif David W. — Chief Financial Officer | Grant/award (A): 239,000 (derivative) @ $0 | EDGAR |
| 2021-04-19 | 4 | Corcoran Gavin — Chief R&D Officer | Grant/award (A): 244,300 (derivative) @ $0 | EDGAR |
| 2021-04-19 | 4 | Cheruvu Pavan — Chief Executive Officer, Director | Grant/award (A): 682,100 (derivative) @ $0 | EDGAR |
| 2021-04-19 | 4 | Vuori Kristiina MD — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2021-03-24 | 4 | Cheruvu Pavan — Chief Executive Officer, Director | Purchase (P): 100,000 @ $2.48 | EDGAR |
| 2021-03-22 | 4 | Nassif David W. — Chief Financial Officer | Grant/award (A): 15,060 @ $0 · Disposition to issuer (D): 15,060 (derivative) @ $0 | EDGAR |
| 2021-03-19 | 4 | Corcoran Gavin — Chief R&D Officer | Grant/award (A): 16,001 @ $0 · Disposition to issuer (D): 16,001 (derivative) @ $0 | EDGAR |
| 2021-03-19 | 4 | Cheruvu Pavan — Chief Executive Officer, Director | Grant/award (A): 22,590 @ $0 · Disposition to issuer (D): 22,590 (derivative) @ $0 | EDGAR |
| 2020-11-25 | 4 | Pande Atul — Director | Purchase (P): 10,000 @ $2.34 | EDGAR |
Recent 8-K events — Sio Gene Therapies Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-04-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2023-03-15 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2023-02-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-12-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-09-14 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2022-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-06-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-04-27 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition ? 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-03-18 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SIOX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs